The recent directive of the Jammu & Kashmir and Ladakh High Court to the Managing Director of the Jammu and Kashmir Medical Supplies Corporation Limited (JKMSCL) has exposed a deeply unsettling truth about the Union Territory’s healthcare administration. Hospitals are meant to be sanctuaries of healing — not places where patients are left helpless due to the non-availability of life-saving drugs. Yet, it took judicial intervention to remind officials of their most basic duty: to ensure uninterrupted access to essential medicines.
The case before the court was not an isolated logistical lapse; it was a symptom of systemic failure. Petitioners highlighted the shocking shortage of crucial anti-haemophilic drugs such as Factor VIII, Factor IX, and Von Willebrand Factor — medicines that literally make the difference between life and death for haemophilia patients. Reports that around 51 patients remain untreated due to the absence of Factor IX are not just administrative oversights — they border on a violation of the fundamental right to health.
JKMSCL was established precisely to prevent such crises. Its creation aimed to streamline drug procurement, promote transparency, and ensure timely supply to every hospital. That the High Court now has to intervene to restore this basic function is an indictment not just of the corporation, but of the broader health governance machinery. The silence and passivity of supervisory officials raise uncomfortable questions: are these failures being overlooked, or has a deeper culture of complacency taken root within the system?
Equally troubling is that this matter reached the public eye only because concerned citizens approached the judiciary. Without their vigilance, the plight of haemophilia patients might have remained hidden under bureaucratic indifference. In an era of digital dashboards, e-tendering, and real-time monitoring, ignorance is no longer an excuse. When technology exists to track every vial and batch, the continuing scarcity of life-saving drugs reflects sheer administrative negligence.
Access to essential medicines cannot be a privilege of the few. For poor patients, the absence of a single drug often decides the line between life and death. The government must move beyond paper compliance and press releases. It must institute real-time tracking of critical drug inventories, fix personal accountability for lapses, and ensure that every healthcare institution — from tertiary hospitals to rural health centres — maintains a full and transparent stock of life-saving medicines.
The High Court’s directive is more than a legal order — it is a moral reminder. The right to health is not a favour extended by the state; it is a constitutional promise. It’s time the administration treated it as such.
